This activity is expired and is no longer available for CME credit.


Diabetic Retinopathy: Preserving Vision through Early Intervention

Author(s)/Faculty: W. Lloyd Clark, MD; Charles C. Wykoff, MD, PhD; Judy E. Kim, MD
Release Date: 1/29/2021Expiration Date: 1/28/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0
Content Type: VideoProvider:
Early intervention with intravitreal antivascular endothelial growth factor (anti-VEGF) therapies has demonstrated significant slowing of disease progression and reduced vision-threatening complications in diabetic retinopathy (DR). Integration of anti-VEGF therapies into treatment paradigms for DR have the potential to significantly enhance clinical outcomes and improve quality-of-life measures for these patients. Within this CME activity, experts in the field will review evidence for the utilization of anti-VEGF therapy early in the disease process of DR, evaluate evidence-based anti-VEGF injection protocols for their ability to achieve long-term benefit in patients with DR, as well as compare current therapeutic regimens for their potential to achieve disease regression.